Neurohumoral changes in patients with left ventricular dysfunction following acute myocardial infarction and the effect of nitrate therapy: A randomized, double-blind, placebo-controlled long-term study

Journal of Cardiovascular Pharmacology

Volumn 48, Issue 4, 2006, Pages 166-172

  Tingberg, Erik ^a   Roijer, Anders ^a   Thilen, Ulf ^a   Öhlin, Hans ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Heart failure; Myocardial infarction; Neurohumoral activation; Nitrates

Indexed keywords

ADRENALIN; ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CALCITONIN GENE RELATED PEPTIDE; ISOSORBIDE 5 NITRATE; NEUROHORMONE; NEUROPEPTIDE Y; NORADRENALIN; PLACEBO; RENIN; SUBSTANCE P; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOPRESSIN;

ACUTE HEART INFARCTION; ADRENALIN BLOOD LEVEL; ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELECTROCARDIOGRAM; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMICS; HORMONAL REGULATION; HUMAN; IMMUNOREACTIVITY; LONG TERM CARE; MALE; NORADRENALIN BLOOD LEVEL; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VASOPRESSIN BLOOD LEVEL;

ADULT; AGED; ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; FEMALE; HUMANS; ISOSORBIDE DINITRATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; NOREPINEPHRINE; RENIN; SUBSTANCE P; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33750618265     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000246149.92535.59     Document Type: Article

References (38)

1. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547-1552.
2. Taylor AL, Ziesche S, Yancy C, et al. African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049-2057.
3. Tingberg E, Roijer A, Thilen U, et al. Randomized, double-blind, placebocontrolled long-term study of isosorbide-5-mononitrate therapy in patients with left ventricular dysfunction after acute myocardial infarction. Am Heart J. 2003;145:e1.
4. Tingberg E, Ohlin AK, Gottsäter A, et al. Lipid peroxidation is not increased in heart failure patients on modern pharmacological therapy. Int J Cardiol. 2005 Nov 23;[Epub ahead of print].
5. Kraiczi H, Karlsson G, Ekman R. Analytical extraction of regulatory peptides from rat lung tissue. Peptides. 1997;18:1597-1601.
6. Rooke P, Baylis PH. A new sensitive radioimmunoassay for plasma arginine vasopressin. J Immunoassay. 1982;3:115-131.
7. van der Hoorn FA, Boomsma F, Man in't Veld AJ, et al. Determination of catecholamines in human plasma by high-performance liquid chromatography: Comparison between a new method with fluorescence detection and an established method with electrochemical detection. J Chromatogr. 1989;487:17-28.
8. Ikeda I, Iinuma K, Takai M, et al. Measurement of plasma renin activity by a simple solid phase radioimmunoassay. J Clin Endocrinol Metab. 1982;54:423-428.
9. Hegbrant J, Thysell H, Ekman R. Plasma levels of vasoactive regulatory peptides in patients receiving regular hemodialysis treatment. Scand J Urol Nephrol. 1992;26:169-176.
10. SHINORA BNP Kit Catalog May 1998, version 04 [ package insert]. Osaka, Japan: CIS Bio International;1998.
11. Olivari MT, Carlyle PF, Levine TB et al. Hemodynamic and hormonal response to transdermal nitroglycerin in normal subjects and patients with congestive heart failure. J Am Coll Cardiol. 1983;2:872-878.
12. Elkayam U, Roth A, Hendriquez B, et al. The hemodynamic and hormonal effects of high dose transdermal nitroglycerin in patients with chronic congestive heart failure. Am J Cardiol. 1985;56:555-559.
13. Shotan A, Mehra A, Ostrzega E, et al. Plasma cyclic guanosine monophosphate in chronic heart failure: hemodynamic and neurohormonal correlations and response to nitrate therapy. Clin Pharmacol Ther. 1993;54:638-644.
14. Lewis BS, Rabinowitz B, Schlesinger Z, et al. Effects of isosorbide-5-mononitrate on exercise performance and clinical status in patients with congestive heart failure. Results of the Nitrates in Congestive Heart Failure (NICE) Study. Cardiology. 1999;91:1-7.
15. Hall AS, Winter C, Bogle SM, et al. The Acute Infarction Ramipril Efficacy (AIRE) Study: rationale, design, organization, and outcome definitions. J Cardiovasc Pharmacol. 1991;18(Suppl 2):S105-109.
16. Rouleau JL, Moye LA, de Camplain J, et al. Activation of neurohormonal systems following acute myocardial infarction. Am J Cardiol. 1991;68:80D-86D. Review
17. McAlpine HM, Morton JJ, Leckie B, et al. Neuroendocrine activation after acute myocardial infarction. Br Heart J. 1988;60:117-124.
18. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
19. Persson H, Andreasson K, Kahan T, et al. Neurohormonal activation in heart failure after acute myocardial infarction treated with beta-receptor antagonists. Eur J Heart Fail. 2002;4:73-82.
20. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724-1729.
21. Webster MW, Fitzpatrick MA, Hamilton EJ, et al. Effects of enalapril on clinical status, biochemistry, exercise performance and hemodynamics in heart failure. Drugs. 1985;30(Suppl 1):74-81.
22. Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation. 2001;103:72-77.
23. Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990;82:1730-1736.
24. Goldsmith SR, Francis GS, Cowley AW Jr, et al. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol. 1983;1:1385-1390.
25. Pernow J, Lundberg JM, Kaijser L, et al. Plasma neuropeptide Y-like immunoreactivity and catecholamines during various degrees of sympathetic activation in man. Clin Physiol. 1986;6:561-578.
26. Edvinsson L, Håkansson R, Wahlstedt C, et al. Effects of neuropeptide Y on the cardiovascular system. Trends Pharmac Sci. 1987;8:231-235.
27. Feng QP, Hedner T, Andersson B, et al. Cardiac neuropeptide Y and noradrenalin balance in patients with congestive heart failure. Br Heart J. 1994;71:261-267.
28. Edvinsson L, Ekman R, Hedner P, et al. Congestive heart failure: involvement of perivascular peptides reflecting activity in sympathetic, parasympathetic and afferent fibres. Eur J Clin Invest. 1990;20:85-89.
29. Valdemarsson S, Edvinsson L, Ekman R, et al. Increased plasma level of substance P in patients with severe congestive heart failure treated with ACE inhibitors. J Intern Med. 1991;230:325-331.
30. Feuerstein G,Willette R, Aiyar N. Clinical perspectives of calcitonin gene related peptide pharmacology. Can J Physiol Pharmacol. 1995;73:1070-1074.
31. Taquet H, Komajda M, Grenier O, et al. Plasma calcitonin gene-related peptide decreases in chronic congestive heart failure. Eur Heart J. 1992;13:1473-1476.
32. Henning RJ, Sawmiller DR. Vasoactive intestinal peptide: cardiovascular effects. Cardiovasc Res. 2001;49:27-37.
33. Lucia P, Caiola S, Coppola A, et al. Vasoactive intestinal peptide (VIP): a new neuroendocrine marker of clinical progression in chronic heart failure? Clin Endocrinol (Oxf). 2003;59:723-727.
34. Iwanaga Y, Nishi I, Furuichi S, et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol. 2006;47:742-748.
35. Davila DF, Nunez TJ, Odreman R, et al. Mechanisms of neurohormonal activation in chronic congestive heart failure: pathophysiology and therapeutic implications. Int J Cardiol. 2005;101:343-346.
36. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126-1130.
37. Pernow J, Schwieler J, Kahan T, et al. Influence of sympathetic discharge pattern on norepinephrine and neuropeptide Y release. Am J Physiol. 1989;257:H866-872.
38. Caiola S, Lucia P, Coppola A, et al. Neuroendocrine activation in acute myocardial infarction: state of the art and preliminary results on intestinal vasoactive peptide. Ann Ist Super Sanita. 1996;32:339-343.